A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome - Trial NCT05754957
Access comprehensive clinical trial information for NCT05754957 through Pure Global AI's free database. This Phase 3 trial is sponsored by Janssen Research & Development, LLC and is currently Recruiting. The study focuses on Acute Coronary Syndrome. Target enrollment is 16000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Janssen Research & Development, LLC
Timeline & Enrollment
Phase 3
Apr 07, 2023
Oct 20, 2026
Primary Outcome
Time to First Occurrence of Major Adverse Cardiovascular Event (MACE)
Summary
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition
 to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the
 composite of cardiovascular [CV] death, myocardial infarction [MI], and ischemic stroke).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05754957
Non-Device Trial